NASDAQ:FBIO - Fortress Biotech Stock Price, Forecast & News

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Fortress Biotech (NASDAQ:FBIO) posted its quarterly earnings data on Friday, August, 9th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the Zacks' consensus estimate of ($0.46) by $0.22. The biopharmaceutical company had revenue of $9.25 million for the quarter, compared to the consensus estimate of $7.51 million. Fortress Biotech had a negative return on equity of 131.74% and a negative net margin of 143.08%. View Fortress Biotech's Earnings History.

Fortress Biotech is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Fortress Biotech.

5 analysts have issued 1-year target prices for Fortress Biotech's shares. Their forecasts range from $4.00 to $19.00. On average, they expect Fortress Biotech's stock price to reach $9.80 in the next twelve months. This suggests a possible upside of 281.3% from the stock's current price. View Analyst Price Targets for Fortress Biotech.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fortress Biotech.

Media headlines about FBIO stock have trended neutral on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Fortress Biotech earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Fortress Biotech.

Fortress Biotech saw a increase in short interest in January. As of January 15th, there was short interest totalling 1,090,000 shares, an increase of 64.2% from the December 31st total of 664,000 shares. Based on an average daily volume of 328,600 shares, the short-interest ratio is presently 3.3 days. Approximately 2.2% of the shares of the company are sold short. View Fortress Biotech's Current Options Chain.

Some companies that are related to Fortress Biotech include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Geron (GERN), Advanced Micro Devices (AMD), Aduro BioTech (ADRO), vTv Therapeutics (VTVT), Vaxart (VXRT), Protalix Biotherapeutics (PLX) and AcelRx Pharmaceuticals (ACRX).

Fortress Biotech's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Cpwm LLC (0.57%), Renaissance Technologies LLC (0.52%), Shikiar Asset Management Inc. (0.44%), Oxford Asset Management LLP (0.35%), Credit Suisse AG (0.16%) and Bank of New York Mellon Corp (0.12%). Company insiders that own Fortress Biotech stock include George Avgerinos and Robyn Hunter. View Institutional Ownership Trends for Fortress Biotech.

FBIO stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP and State Street Corp. View Insider Buying and Selling for Fortress Biotech.

FBIO stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Oxford Asset Management LLP, Shikiar Asset Management Inc., Credit Suisse AG, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Banco Bilbao Vizcaya Argentaria S.A. and Alpine Global Management LLC. View Insider Buying and Selling for Fortress Biotech.

Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FBIO stock can currently be purchased for approximately $2.57.

Fortress Biotech has a market capitalization of $181.90 million and generates $26.88 million in revenue each year. The biopharmaceutical company earns $-84,150,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Fortress Biotech employs 68 workers across the globe.View Additional Information About Fortress Biotech.

The official website for Fortress Biotech is http://www.fortressbiotech.com/.

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]